本文選題：輔助用藥 + 合理用藥�。� 參考：《中國(guó)藥房》2016年23期

【摘要】：目的:為促進(jìn)臨床合理用藥及衛(wèi)生行政部門制定用藥政策提供依據(jù)。方法:對(duì)西安地區(qū)11家三級(jí)醫(yī)院2013-2015年銷售金額排名前20位的藥品中輔助用藥的總銷售金額及構(gòu)成比、單品種銷售金額、用藥頻度(DDDs)、日均費(fèi)用(DDC)等數(shù)據(jù)及不良反應(yīng)情況進(jìn)行統(tǒng)計(jì)分析。結(jié)果:西安地區(qū)11家三級(jí)醫(yī)院2013-2015年輔助用藥的總銷售金額及構(gòu)成比均呈上升趨勢(shì),3年間輔助用藥銷售金額構(gòu)成比分別為8.43%、10.25%、12.20%。共有13種輔助用藥至少1年進(jìn)入3家以上醫(yī)院藥品總銷售金額排名前20位;其中,小牛血清去蛋白注射液、前列地爾注射液和丹紅注射液銷售金額各年度均穩(wěn)居前4位,注射用丹參多酚酸鹽2014-2015年進(jìn)入前3位;前列地爾注射液、血栓通注射和脾氨肽口服凍干粉各年度DDDs均居前3位;脾多肽注射液、注射用益氣復(fù)脈和腦苷肌肽注射液DDC居前3位,分別為885.24、372.34和349.37元。輔助用藥不良反應(yīng)發(fā)生率逐年升高,由2013年的9.13%上升至2015年的13.49%。結(jié)論:輔助用藥已成為西安地區(qū)醫(yī)院臨床用藥的重要組成部分,其銷售金額、用量增長(zhǎng)較快。臨床需要加強(qiáng)對(duì)輔助用藥的管控,密切關(guān)注其安全性問(wèn)題,控制醫(yī)療費(fèi)用不合理增長(zhǎng)。
[Abstract]:Objective: to provide the basis for the rational use of drugs in clinic and the formulation of drug use policy by health administration department. Methods: the total sales amount and composition ratio of auxiliary drugs in 11 tertiary hospitals in Xi'an from 2013 to 2015 were analyzed. DDDs, DDC and ADRs were statistically analyzed. Results: the total sales amount and composition ratio of supplementary drugs in 11 tertiary hospitals in Xi'an area showed an upward trend in 2013-2015. The proportion of total sales amount of supplementary drugs in Xi'an region in the past three years was 8.4310.25 and 12.20, respectively. A total of 13 kinds of adjuvant drugs entered at least one year into the top 20 of the total sales amount of drugs in 3 or more hospitals, among which, calf serum deproteinizing injection, alprostadil injection and Danhong injection were among the top 4 in each year. Salvia miltiorrhiza polyphenolic acid for injection came into the top 3 in 2014-2015, prostadil injection, Xue Tong injection and spleen aminopeptide oral lyophilized powder ranked first 3 in each year, spleen polypeptide injection, invigorating qi and supplementing pulse for injection and cerebral glycoside carnosine injection DDC ranked the top 3, It was 885.24372.34 and 349.37 yuan respectively. The incidence of ADRs increased from 9.13% in 2013 to 13.49% in 2015. Conclusion: adjuvant drug has become an important part of clinical use in Xi'an district hospital. It is necessary to strengthen the control of adjuvant drugs, pay close attention to its safety and control the unreasonable increase of medical expenses.
【作者單位】： 西安市第四醫(yī)院藥劑科;
【分類號(hào)】：R969.3

【相似文獻(xiàn)】

相關(guān)期刊論文 前5條

1 韓冰;喻軼群;楊其蓮;沈春英;林曉敏;;2010—2011年上海市閔行區(qū)中心醫(yī)院輔助用藥使用分析[J];實(shí)用醫(yī)技雜志;2013年03期

2 賴延錦;;淺談?shì)o助用藥在臨床藥物治療中的價(jià)值[J];中國(guó)醫(yī)藥指南;2014年13期

3 張忠太;胡學(xué)敏;盧宏麗;劉凌燕;;臨床常用輔助用藥的藥性探析[J];山西醫(yī)藥雜志(下半月刊);2008年11期

4 賈立華;郭曉華;陳珊珊;丁橋蘭;王愛(ài)莉;;我院2000年～2003年抗腫瘤輔助用藥分析[J];解放軍藥學(xué)學(xué)報(bào);2005年06期

5 ;[J];;年期

相關(guān)重要報(bào)紙文章 前1條

1 何洪靜 成都軍區(qū)昆明總醫(yī)院藥劑科;輔助用藥莫“喧賓奪主”[N];醫(yī)藥經(jīng)濟(jì)報(bào);2013年

，

本文編號(hào)：2077663